International Journal of Healthcare Sciences ISSN 2348-5728 (Online)
Vol. 4, Issue 2, pp: (522-528), Month: October 2016 - March 2017, Available at: www.researchpublish.com

Intestinal Microbiota Transplantation (IMT) For Recurrent Clostridium Difficile Infection (CDI)

[1]Sharifah Radhi Alsammak, [2]Fatimah Abdullah Al Zaher,
[3]Basmah Baqer Ali Alshammasi, [4]Noor Baqer Ali Alshamase, [5]Zahra Zaki Al Zahir

Abstract: **Clostridium difficile infection (CDI) is a intestinal disease believed to be causally related to perturbations to the intestinal microbiota. The term microbaiota describes the neighborhood of bacteria that live in a specific area of the body. *This overview aimed to discuss and highlight the most recent evidence about* intestinal microbiota transplantation for recurrent Clostridium difficile infection, through systematically reviewing articles concerning the same topic. We performed an electronic search through Medline, and Embase databases (up to November 2016) for publications, we limited our search to English language Articles, and to every study discussing Fecal bacteriotherapy, which is also called intestinal microbiota transplantation (IMT) as treatment for recurrent Clostridium difficile infection. The role of IMT has actually come a long way from its start in transfaunation, and we are simply in the dawn of realizing its full potential to treat a range of gastrointestinal disorders. Most promising is its function in CDI, which has become a life-threatening and financially crippling epidemic in healthcare worldwide. With a much better understanding of the complexities of the colonic microbiome and its role in colonic pathophysiology, IMT has the potential to become the requirement of take care of CDI treatment, and might be the potential answer to other intestinal conditions in years to come.**

Keywords: **CDI treatment, intestinal microbiota transplantation (IMT), Embase databases.**

1. INTRODUCTION

Clostridium difficile infection (CDI) is a intestinal disease believed to be causally related to perturbations to the intestinal microbiota. The term microbaiota describes the neighborhood of bacteria that live in a specific area of the body [(1, 2)]. The human gut microbiota is a varied ecosystem consisting of countless bacterial types [(3)]. It is believed that one role of this community is to protect against invasion by pathogens [(4,5)]. The primary understanding of the pathogenesis of CDI is that it needs disturbance of the gut microbiota as a requirement for the beginning of symptomatic disease (**Figure 1**) [(6)]. This disturbance usually takes place through exposure to prescription antibiotics, which modify the composition and function of the microbiome to a state susceptible to CDI [(7)]. After direct exposure to C difficile spores, patients can either end up being asymptomatically colonized or establish symptomatic infection [(8,9)]. Colonization follows germination of the C difficile spores and vegetative outgrowth. Subsequent expression of the toxic substances TcdA and TcdB, the primary virulence elements of C difficile, leads to epithelial damage and symptomatic infection. CDI can be self-limited [(10,11)] but normally requires treatment with antibiotics that have activity versus C difficile, [(12)] although the treatments are nonspecific and have activity versus other gut germs. Features of infection consist of diarrhea, leukocytosis, fever, or pseudomembranous colitis [(12)].

Regardless of traditional CDI antibiotic treatment, recurrence is common and leads to substantial morbidity, cost, and decrease in lifestyle after transplantation. Fecal microbiota transplantation (FMT) is a unique technique of restoring balance to the GIMb. When utilized to deal with refractory or reoccurring CDI, FMT is very effective in immunocompetent patients [(13)]. Recent information suggests that, with careful donor screening, FMT can be securely

performed in immunocompromised patients [14]. To this day nevertheless, little experience with FMT in HSCT receivers has been reported in the literature [2,15].

Fecal Bacteriotherapy, likewise called intestinal microbiota transplantation (IMT), may be an useful treatment for CDI through repair of the intestinal microbiota [16]. IMT has actually not been commonly adopted as a healing tool probably due to issues concerning security and reputation [17]. Despite these issues, the procedure has been carried out in a growing number of patients throughout the world. In addition to dealing with CDI, IMT has likewise been utilized to treat pseudomembranous colitis (PMC), thought to be caused by C. difficile toxins, inflammatory bowel disease and irritable bowel syndrome (IBS), 2 diseases also believed to be causally related to the intestinal microbiota [18].



Figure1: Pathogenesis of Clostridium difficile infection (CDI).

This overview aimed to discuss and highlight the most recent evidence about intestinal microbiota transplantation for recurrent Clostridium difficile infection, through systematically reviewing articles concerning the same topic.

2. METHODOLOGY

We performed an electronic search through Medline, and Embase databases (up to November 2016) for publications, we limited our search to English language Articles, and to every study discussing Fecal bacteriotherapy, which is also called intestinal microbiota transplantation (IMT) as treatment for recurrent Clostridium difficile infection

Publications of any type were included if they reported original data from such a procedure for CDI or treatment with IMT treatment. Bibliographies of all identified reviews and original research publications were hand searched for additional studies. We also searched Current Contents, Conference Papers Index, and Web of Science for conference proceedings and abstracts that may not have been indexed in these 3 databases.

3. RESULTS AND DISCUSSION

Recurrent CDI:

After healing from infection, some patients keep a microbiome vulnerable to CDI and can have recurrent disease (see **Figure1**), [19] Recurrent CDI has been documented to happen in as lots of as 15% to 30% of patients after a preliminary bout of CDI. Certainly, some patients suffer from multiple bouts of persistent infection, with as numerous as Z10 episodes. Particularly, as much as 65% of patients who experience 1 reoccurrence will have subsequent reoccurrences after antibiotic treatment is stopped [20,21,22]. Traditional therapies for recurrent CDI consist of extended pulses and/or tapering doses of either metronidazole or (usually) vancomycin [12,23]. Multiple routines exist and the period differs from 4 to 10 weeks, followed in some instances by either rifaximin or fidaxomicin as a cap or chaser after preliminary treatment [12,24,25]. The possible system by which this acts involves representatives with a narrower spectrum of antimicrobial activity, enabling the microbiome to recuperate while still reducing C difficile activity.

Some patients have frequent CDI recalcitrant to these treatments and regression soon after prescription antibiotics are stopped. A trial of chronic, low-dose prescription antibiotics to suppress CDI is a choice, although there are drawbacks to this method-- increased antimicrobial resistance, continued microbiome disruption, and advancements requiring retreatment at greater doses. Confronted with this possibility, other healing options are typically gone over in these patients. It is uncertain why patients experience frequent infection, however host aspects such as antibody action to toxins [26], microbial elements such as C difficile stress [27,28], and community elements such as persistent disturbance of the gut microbiome [29] all might contribute. Enhancement of the immune reaction through intravenous infusion of immunoglobulin has variable efficacy [30]. A strain-dependent differential reoccurrence rate for treatment, either of primary CDI or of a very first reoccurrence, with the antibiotic fidaxomicin has been demonstrated [19,31]. It is not clear how this translates into clinical benefit, especially for those with numerous reoccurrences. Restoration of the gut microbiome is the treatment method that has garnered the most attention and has actually gotten acceptance among practitioners for treatment of reoccurring CDI [32].

History of Intestinal Microbiota Transplantation(IMT) and Preparation method:

IMT, which utilizes healthy stool to restore the microbiome to a state resistant to CDI, has recently reemerged as a reliable and safe alternative for treatment of frequent CDI. IMT is not new to modern-day times, as there are reports of its usage in ancient China for different purposes [33]. It was first described as a treatment of pseudomembranous colitis in the 1950s [34] then is not well-described in the literature again up until 1983, when Schwann and colleagues [35] published the use of fecal enema to treat a 65-year-old lady with CDI, who had symptomatic resolution within 24 hours. The variety of protocols and possible paths of administration increased: Colleagues and Aas [36] reported utilizing IMT through nasogastric infusion of stool in 1994; Persky and Brandt [37] performed IMT via colonoscopy in 2000; and in 2010, Silverman and associates [38] reported a case series of self-administered FMTs through fecal retention enemas by patients in their own homes. In the past a number of years, making use of IMT for CDI has become prevalent.

Preparation and infusion of donor stool for IMT takes myriad forms, as reported in the published procedures [39,40,41]. Diluents usually include faucet water or typical saline, however yogurt, milk, and mixtures with psyllium husk have actually likewise been utilized. Some protocols call for mild agitation of stool with the diluent, while others blend the whole preparation. Often, stool is collected and prepared within hours of administration, however frozen stool preparations gathered weeks or months before IMT have actually also been effectively used [42]. The quantity of ready stool infusate likewise differs but is normally a minimum of 50 g.

IMT Site of application:

The sites of stool instillation consist of the stomach, duodenum, and proximal/distal large intestinal tract [40,41]. Infusion into the upper GI tract takes place through a nasogastric or nasojejunal tube or by means of gastroscopy. Infusion into the lower GI system happens utilizing retention enemas, which the patients self-administer in some protocols [38], or via colonoscopy, which typically infuses the donor stool into the terminal ileum and other websites more distal as the colonoscope is withdrawn.

Preparation of the patient prior to the stool instillation:

Recipients of stool instillations must be pretreated with oral vancomycin before to the treatment to decrease the problem of vegetative C. difficile nests. The dosing and period of vancomycin treatment offered prior to the stool instillation

procedure has actually varied from 250 mg TID for 4 days [36] to 500 mg BID for 7 days [43] and continues until the evening before the procedure. In addition, patients who received their stool instillation through the upper GI tract received omeprazole 20 mg by oral route the evening before and the morning of the treatment, to decrease gastric hydrochloric acid production and to create a maximally responsive environment for vegetative germs instilled into the proximal small intestine [36]. For those patients who receive the stool as an enema, Borody [43] and Nieuwdorp [44] have actually advised a single oral lavage with a purgative (such as polyethylene glycol with electrolytes) on the day of the treatment. Nieuwdorp et al. also employed colon lavage for each of their 4 patients prior to feces instillation via the upper GI system [44].

Table1: Screening tests for potentially transmissible infectious pathogens in donors and recipients undergoing fecal microbiota transplantation

Pathogen/Infection	Usual Tests	Recipient, Donor, or Both	Part of Routine or Extended Screening
Hepatitis A/B/C	Serum antibodies; serum PCR	Both	Routine
HIV	Third- or fourth-generation serum ELISA; serum RNA PCR if recent seroconversion possible	Both	Routine
Syphilis	Nontreponemal serum test followed by treponemal confirmatory test if positive (eg, serum RPR followed by TP-PA)	Both	Routine
Enteric bacterial pathogens (*Salmonella* species, *E coli*, *Shigella* species, and others)	Routine stool culture	Donor	Routine
Enteric helminths and protozoa	Stool microscopy for ova and parasites; antigen ELISAs for *Giardia* and *Cryptosporidium* species	Donor	Routine
Clostridium difficile	Stool EIA for bacterial products and/or PCR	Donor	Routine
Epstein-Barr virus	Serum antibodies; PCR	Both	Extended (HSCT and SOT patients)
Cytomegalovirus	Serum antibodies; PCR	Both	Extended (HSCT and SOT patients)
Others (*Helicobacter pylori*, HTLV, and many others)	Various tests	Usually donor only	Extended (research protocols)

Recipients are generally screened for blood-borne pathogens (**Table 1**) to develop whether there is evidence of prior infection, which can be useful post-FMT if a transmission is believed. Some protocols call for use of an antimotility agent such as loperamide before FMT, to help in retention of the transplant [39].

We have identified one large systematic review study [45] that have summarized the literature explaining patients treated with IMT for recurrent CDI. This research study was involving evidence from 317 patients across 27 case series and reports suggests that IMT is a highly efficient treatment for these disorders when basic treatments have actually failed. IMT led to resolution for 92% of patients (89% after a single treatment). Regressions and deaths after IMT were fairly unusual. Concluded that IMT was extremely reliable, showing disease resolution in 92% of cases. Effectiveness differed by route of instillation, relationship to stool donor, volume of IMT given, and treatment before infusion. Death and negative events were unusual. These findings can direct doctors thinking about executing the treatment till much better designed studies are carried out to confirm finest practices [45].

4. CONCLUSION

The role of IMT has actually come a long way from its start in transfaunation, and we are simply in the dawn of realizing its full potential to treat a range of gastrointestinal disorders. Most promising is its function in CDI, which has become a life-threatening and financially crippling epidemic in healthcare worldwide. With a much better understanding of the complexities of the colonic microbiome and its role in colonic pathophysiology, IMT has the potential to become the requirement of take care of CDI treatment, and might be the potential answer to other intestinal conditions in years to come. Fecal biotherapy is a" low tech" treatment that can be carried out in a lot of healthcare institutions. There are numerous compelling factors for considering fecal bacteriotherapy for patients who have been strained by recurrent CDI. Crucial reasons include the reduced danger of antimicrobial drug allergic reaction and development of antibiotic resistant bacteria that may be connected with duplicated courses of systemic antimicrobial representatives.

REFERENCES

[1] Callejas-Diaz A, Gea-Banacloche JC. Clostridium difficile: deleterious impact on hematopoietic stem cell transplantation. Current hematologic malignancy reports. 2014; 9 (1): 85–90.

[2] Neemann K, Eichele DD, Smith PW, Bociek R, Akhtari M, Freifeld A. Fecal microbiota transplantation for fulminant Clostridium difficile infection in an allogeneic stem cell transplant patient. Transpl Infect Dis 2012; 14 (6): E161–165.

[3] Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. Nature. 2012; 486(7402):222–227.

[4] Van der Waaij D, Berghuis-de Vries JM, Lekkerkerk-van der Wees JE. Colonization resistance of the digestive tract in conventional and antibiotic-treated mice. Epidemiol Infect. 1971;69(03):405–411.

[5] Vollaard E, Clasener H. Colonization resistance. Antimicrob Agents Chemother. 1994;38(3):409.

[6] Britton RA, Young VB. Role of the intestinal microbiota in resistance to colonization by *Clostridium difficile*. Gastroenterology. 2014;146(6):1547–1553.

[7] Theriot CM, Koenigsknecht MJ, Carlson PE, Jr, et al. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to *Clostridium difficile* infection. Nat Commun.2014;5:3114.

[8] Samore MH, DeGirolami PC, Tlucko A, et al. *Clostridium difficile* colonization and diarrhea at a tertiary care hospital. Clin Infect Dis. 1994;18(2):181–187.

[9] Riggs MM, Sethi AK, Zabarsky TF, et al. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic *Clostridium difficile* strains among long-term care facility residents. Clin Infect Dis. 2007; 45(8): 992–998.

[10] Bartlett JG. Treatment of antibiotic-associated pseudomembranous colitis. Rev Infect Dis. 1984;6(Suppl 1):S235–S241.

[11] Olson MM, Shanholtzer CJ, Lee JT, Jr, et al. Ten years of prospective *Clostridium difficile*-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982–1991. Infect Control Hosp Epidemiol. 1994;15(6):371–381.

[12] Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for *Clostridium difficile* infection. Clin Microbiol Infect.2014;20(Suppl 2):1–26.

[13] Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013; 108 (4): 500–508.

[14] Kelly CR, Ihunnah C, Fischer M, et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 2014; 109 (7): 1065–1071.

[15] de Castro CG Jr, Ganc AJ, Ganc RL, Petrolli MS, Hamerschlack N. Fecal microbiota transplant after hematopoietic SCT: report of a successful case. Bone Marrow Transplant 2015; 50 (1): 145.

[16] Huebner ES, Surawicz CM. Treatment of recurrent Clostridium difficile diarrhea. Gastroenterol Hepatol (N Y) 2006;2:203-8.

[17] Famularo G, Trinchieri V, De Simone C. Fecal bacteriotherapy or probiotics for the treatment of intestinal diseases? Am J Gastroenterol 2001;96:2262-4.

[18] Borody TJ, Warren EF, Leis SM, Surace R, Ashman O, Siarakas S. Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterol 2004;38:475-83.

[19] Figueroa I, Johnson S, Sambol SP, et al. Relapse versus reinfection: recurrent *Clostridium difficile*infection following treatment with fidaxomicin or vancomycin. Clin Infect Dis. 2012;55(Suppl 2):S104–S109.

[20] Bakken JS. Fecal bacteriotherapy for recurrent *Clostridium difficile* infection. Anaerobe.2009;15(6):285–289.

[21] Huebner ES, Surawicz CM. Treatment of recurrent *Clostridium difficile* diarrhea. Gastroenterol Hepatol. 2006; 2(3):203–208.

[22] Borody TJ, Warren EF, Leis SM, et al. Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterol. 2004;38(6):475–483.

[23] McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent *Clostridium difficile* disease. Am J Gastroenterol. 2002;97(7):1769–1775.

[24] Garey KW, Ghantoji SS, Shah DN, et al. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with *Clostridium difficile* infection. J Antimicrob Chemother. 2011;66(12):2850–2855.

[25] Johnson S, Gerding DN. Fidaxomicin 'chaser' regimen following vancomycin for patients with multiple *C difficile* recurrences. Clin Infect Dis. 2012;56(2):309–310.

[26] Kyne L, Warny M, Qamar A, et al. Association between antibody response to toxin A and protection against recurrent *Clostridium difficile* diarrhoea. Lancet. 2001;357(9251):189–193.

[27] Crook DW, Walker AS, Kean Y, et al. Fidaxomicin versus vancomycin for *Clostridium difficile*infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis. 2012;55(Suppl 2):S93–S103.

[28] Abou Chakra CN, Pepin J, Sirard S, et al. Risk factors for recurrence, complications and mortality in *Clostridium difficile* infection: a systematic review. PLoS One. 2014;9(6):e98400.

[29] Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal microbiome in recurrent *Clostridium difficile*–associated diarrhea. J Infect Dis. 2008;197(3):435–438.

[30] O'Horo J, Safdar N. The role of immunoglobulin for the treatment of *Clostridium difficile* infection: a systematic review. Int J Infect Dis. 2009;13(6):663–667.

[31] Cornely OA, Miller MA, Louie TJ, et al. Treatment of first recurrence of *Clostridium difficile* infection: fidaxomicin versus vancomycin. Clin Infect Dis. 2012;55(Suppl 2):S154–S161.

[32] Bakken JS, Polgreen PM, Beekmann SE, et al. Treatment approaches including fecal microbiota transplantation for recurrent *Clostridium difficile* infection (RCDI) among infectious disease physicians. Anaerobe. 2013;24:20–24.

[33] Zhang F, Luo W, Shi Y, et al. Should we standardize the 1,700-year-old fecal microbiota transplantation? Am J Gastroenterol. 2012;107(11):1755.

[34] Eiseman B, Silen W, Bascom GS, et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery. 1958;44(5):854–859.

[35] Schwan A, Sjolin S, Trottestam U, et al. Relapsing *Clostridium difficile* enterocolitis cured by rectal infusion of homologous faeces. Lancet. 1983;322(8354):845.

[36] Aas J, Gessert CE, Bakken JS. Recurrent *Clostridium difficile* colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis. 2003;36(5):580–585.

[37] Persky SE, Brandt LJ. Treatment of recurrent *Clostridium difficile*–associated diarrhea by administration of donated stool directly through a colonoscope. Am J Gastroenterol. 2000;95(11):3283–3285.

[38] Silverman MS, Davis I, Pillai DR. Success of self-administered home fecal transplantation for chronic *Clostridium difficile* infection. Clin Gastroenterol Hepatol. 2010;8(5):471–473.

[39] Bakken JS, Borody T, Brandt LJ, et al. Treating *Clostridium difficile* infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol. 2011;9(12):1044–1049.

[40] Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent *Clostridium difficile* infection. Clin Infect Dis. 2011;53(10):994–1002.

[41] Kassam Z, Lee CH, Yuan Y, et al. Fecal microbiota transplantation for *Clostridium difficile* infection: systematic review and meta-analysis. Am J Gastroenterol. 2013;108(4):500–508.

[42] Hamilton MJ, Weingarden AR, Sadowsky MJ, et al. Standardized frozen preparation for transplantation of fecal microbiota for recurrent *Clostridium difficile* infection. Am J Gastroenterol. 2012;107(5):761–767.

[43] Borody, T.J., Leis, S, Pang, G, and Wettstein, AR. Fecal bacteriotherapy in the treatment of recurrent C. difficile infection. Up To Date 14.3. 8-3-2006.

[44] Nieuwdorp M, van Nood E, Speelman P, van Heukelen HA, Jansen JM, Visser CE, et al. [Treatment of recurrent Clostridium difficile-associated diarrhoea with a suspension of donor faeces]. Ned Tijdschr Geneeskd 2008;152:1927–32.

[45] Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis. 2011 Nov;53(10):994-1002.